Study name | Age (Years), Mean (SD) | Gender, Male, N (%) | History of any preventive treatment use, N (%) | History of any preventive treatment failure, N (%) | Migraine Duration (Years), Mean (SD) | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Erenumab 70Â mg | Erenumab 140Â mg | Placebo | Erenumab 70Â mg | Erenumab 140Â mg | Placebo | Erenumab 70Â mg | Erenumab 140Â mg | Placebo | Erenumab 70Â mg | Erenumab 140Â mg | Placebo | ||
Basedau et al. 2024 [17] | 39.1 (12.77) | N/A | 41.58 (11.43) | 6 (15) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Filippi et al. 2023 [35] | N/A | 48·1 (8·83) | 42·6 (11·31) | 5 (12.82) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Yu et al. 2022 (The DRAGON Study) [29] | 41.4 (10.9) | N/A | 41.9 (10.9) | 103 (18.5) | 171 (61.29) | N/A | 178 (64.03) | 80 (28.67) | N/A | 74 (26.62) | 18.2 (11.9) | N/A | 17.8 (11.4) |
Chowdhury et al. 2022 [32] | 34.9 (9.2) | 35.4 (7.2) | 35.3 (8.9) | 74 (21.1) | N/A | N/A | N/A | N/A | N/A | N/A | 6.76 (5.96) | 6.66 (6.54) | 6.87 (5.69) |
Wang et al. 2021 (The EMPOwER Study) [27] | 37.3 (10.0) | 37.1 (9.6) | 38.0 (10.1) | 163(18.11%) | 181 (53.6) | 119 (53.1) | 179 (53.0) | 108 (32.0) | 72 (32.1) | 108 (32.0) | 11.1 (9.5) | 11.2 (9.7) | 12.6 (10.2) |
Takishema et al. 2021 [25] | 44.2 (8.5) | N/A | 44.6 (9.3) | 34(13.02%) | 60 (46.2) | N/A | 50 (38.2) | 59 (45.4) | N/A | 58 (44.3) | N/A | N/A | N/A |
Lanteri-Minet et al. 2021 [21] | N/A | 44·6 (10·5) | 44·2 (10·6) | 46 (18.7) | N/A | N/A | N/A | N/A | 121 (100) | 125 (100) | N/A | N/A | N/A |
Hirata et al. 2021 [19] | 44.0 (8.2) | N/A | 44.5 (9.6) | 25 (14.79) | N/A | N/A | N/A | 37 (41.1) | N/A | 30 (38.0) | 17.71 (11.48) | N/A | 18.9 (11.98) |
Diener et al. 2021 [33] | 41.1 (11.3) | 40.4 (11.1) | 41.3 (11.2) | 141 (14.76) | 133 (42.0) | 124 (38.9) | 131 (41.1) | 127 (40.1) | 116 (36.4) | 127 (39.8) | 19.80 (12.26) | 19.72 (12.31) | 20.05 (12.18) |
Broessner et al. 2020 [30] | 41.1 (11.3) | 40.4 (11.1) | 41.3 (11.2) | 141 (14.76) | 133 (42.0) | 124 (38.9) | 131 (41.1) | 127 (40.1) | 116 (36.4) | 127 (39.8) | N/A | N/A | N/A |
Goadsby et al. 2019 [18] | 41.1 (11.3) | 40.4 (11.1) | 41.3 (11.2) | 141 (14.76) | 133 (42.0) | 124 (38.9) | 131 (41.1) | 127 (40.1) | 116 (36.4) | 127 (39.8) | 19.80 (12.26) | 19.72 (12.31) | 20.05 (12.18) |
Brandes et al. 2019 [28] | 41.4 (11.3) | 42.1 (11.3) | 42.1 (11.3) | 115 (17.2) | 138 (72.3) | 138 (72.3) | 218 (76.2) | 127 (66.5) | 126 (66.3) | 200 (70.0) | N/A | N/A | N/A |
Sakai et al. 2019 [23] | 43 (8.45) | 44.25 (7.86) | 43 (7.68) | 63 (15.44) | 80 (59.3) | 77 (56.2) | 76 (55.9) | 43 (48.9) | 54 (65.1) | 44 (53.0) | N/A | N/A | N/A |
Reuter et al. 2018 (LIBERTY) [22] | N/A | 44·6 (10·5) | 44·2 (10·6) | 46 (18.7) | N/A | N/A | N/A | N/A | 121 (100) | 125 (100) | N/A | N/A | N/A |
Ashina et al. 2018 [16] | 41.4 (11.3) | 42.1 (11.3) | 42.1 (11.3) | 115 (17.2) | 138 (72.3) | 138 (72.3) | 218 (76.2) | 127 (66.5) | 126 (66.3) | 200 (70.0) | 20.7 (12.9) | 21.9 (11.8) | 22.2 (12.7) |
Buse et al. 2018 [31] | 41.1 (11.3) | 40.4 (11.1) | 41.3 (11.2) | 141 (14.76) | 133 (42.0) | 124 (38.9) | 131 (41.1) | 127 (40.1) | 116 (36.4) | 127 (39.8) | 19.80 (12.26) | 19.72 (12.31) | 20.05 (12.18) |
Dodick et al. 2018 [34] | 42 (11) | N/A | 42 (12) | 85 (14.7) | 134 (46.9) | N/A | 132 (45.4) | 117 (87.3) | N/A | 115 (87.1) | 22 (13) | N/A | 20 (12) |
Goadsby et al. 2017 (STRIVE Study) [36] | 41.1 (11.3) | 40.4 (11.1) | 41.3 (11.2) | 141 (14.76) | 133 (42.0) | 124 (38.9) | 131 (41.1) | 127 (40.1) | 116 (36.4) | 127 (39.8) | 19.80 (12.26) | 19.72 (12.31) | 20.05 (12.18) |
Tepper et al. 2017 [26] | 41·4 (11·3) | 42·9 (11·1) | 42·1 (11·3) | 115(17.24%) | N/A | N/A | N/A | 127 (67% | 126 (66%) | 200 (70%) | 20.7 (12.8) | 21.9 (11.8) | 22.2 (12.6) |
Hoon et al. 2017 [20] | N/A | 23.8 (5.85) | 28.5 (11.7) | 3 (25) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Sun et al. 2016 [24] | 42·6 (9·9) | N/A | 41·4 (10·0) | 53(19.85%) | 47 (44%) | N/A | 66 (41%) | 34 (32%) | N/A | 60 (38%) | 21·5 (11·7) | N/A | 20·7 (11·5) |